Player FM - Internet Radio Done Right
Checked 17h ago
Ajouté il y a cinq ans
Contenu fourni par Dr Neil Love. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Dr Neil Love ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Player FM - Application Podcast
Mettez-vous hors ligne avec l'application Player FM !
Mettez-vous hors ligne avec l'application Player FM !
Chronic Lymphocytic Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia
Manage episode 456493805 series 2530615
Contenu fourni par Dr Neil Love. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Dr Neil Love ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics:
- Introduction (0:00)
- Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44)
- Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43)
- Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20)
- Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52)
- Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06)
1413 episodes
Manage episode 456493805 series 2530615
Contenu fourni par Dr Neil Love. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Dr Neil Love ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics:
- Introduction (0:00)
- Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44)
- Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43)
- Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20)
- Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52)
- Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06)
1413 episodes
Tous les épisodes
×R
Research To Practice | Oncology Videos
1 Lymphoma | What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma 2:00:29
2:00:29
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
2:00:29Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Myelofibrosis | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis 1:59:15
1:59:15
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:59:15Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53) Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45) Managing MF for Patients with Anemia — Dr Yacoub (59:47) Future Directions in the Management of MF — Dr Fleischman (1:27:53) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Metastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer 2:01:00
2:01:00
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
2:01:00Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Chronic Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia 1:27:00
1:27:00
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:27:00Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics: Introduction (0:00) Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45) Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23) Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Acute Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia 1:58:51
1:58:51
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:58:51Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei (2:48) Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML — Dr Stone (26:52) Role of FLT3 Inhibitors in AML Management — Dr Perl (49:41) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein (1:13:57) Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang (1:35:50) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer 2:00:37
2:00:37
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
2:00:37Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21) Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36) Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58) Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52) Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24) CME information and select publications…
R
Research To Practice | Oncology Videos
1 HER2-Low and HER2-Ultralow Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer 1:31:29
1:31:29
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:31:29Featuring perspectives from Dr Aditya Bardia, Prof Giuseppe Curigliano, Dr Hope S Rugo and Dr Antonio C Wolff, including the following topics: Introduction (0:00) Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer — Dr Wolff (2:28) Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr Bardia (23:16) Practical Applications of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Metastatic Breast Cancer — Prof Curigliano (51:31) Future Directions for HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Breast Cancer — Dr Rugo (1:11:57) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Multiple Myeloma | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma 1:57:11
1:57:11
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:57:11Featuring perspectives from Dr Sagar Lonial, Prof Philippe Moreau, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski (1:26) Integration of Novel Therapies into the Management of Relapsed/Refractory MM — Dr Richardson (26:53) Chimeric Antigen Receptor T-Cell Therapy for MM — Dr Raje (48:48) Bispecific Antibodies for the Treatment of MM — Prof Moreau (1:12:52) Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial (1:36:32) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Chronic Lymphocytic Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia 1:57:07
1:57:07
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:57:07Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics: Introduction (0:00) Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44) Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20) Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Colorectal and Gastroesophageal Cancers | Cases from the Community: Integrating New Research Findings into Practice 49:11
49:11
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
49:11Featuring perspectives from Dr Christopher Lieu, moderated by Dr Stephen “Fred” Divers CME information and select publications
R
Research To Practice | Oncology Videos
1 Hepatobiliary Cancers | Cases from the Community: Integrating New Research Findings into Practice 55:50
55:50
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
55:50Featuring perspectives from Dr Daneng Li, moderated by Dr Stephen “Fred” Divers CME information and select publications
R
Research To Practice | Oncology Videos
1 Gynecologic Cancers | Cases from the Community: Integrating New Research Findings into Practice 46:42
46:42
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
46:42Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen “Fred” Divers CME information and select publications
R
Research To Practice | Oncology Videos
1 Myelofibrosis | Cases from the Community: Integrating New Research Findings into Practice 51:44
51:44
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
51:44Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen “Fred” Divers CME information and select publications
R
Research To Practice | Oncology Videos
1 ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2 11:59
11:59
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
11:59Featuring an interview with Dr Seth Wander, including the following topics: Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00) EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023; Abstract 188O . (5:50) Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024; Abstract 1027 . (9:43) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Leukemia and Myelodysplastic Syndromes | Cases from the Community: Integrating New Research Findings into Practice 51:45
51:45
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
51:45Featuring perspectives from Dr Harry Paul Erba, moderated by Dr Stephen “Fred” Divers CME information and select publications
Bienvenue sur Lecteur FM!
Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.